Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Quarterly results

Societal CDMO, Inc. (REPH) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/04/2023 4 Lake Ryan David (CFO) has filed a Form 4 on Societal CDMO, Inc.
Txns: Paid exercise price by delivering 1,198 shares @ $0.46, valued at $551.1
08/25/2023 4 Arens Mathew Paul (10% Owner) has filed a Form 4 on Societal CDMO, Inc.
Txns: Bought 6,250,000 shares @ $0.4, valued at $2.5M
Granted 20,000 options to buy @ $0.61, valued at $12.2k
Bought 1,250,000 options to buy @ $0.0001, valued at $125
08/25/2023 3 Arens Mathew Paul (10% Owner) has filed a Form 3 on Societal CDMO, Inc.
08/25/2023 SC 13D First Light Asset Management, LLC reports a 19.7% stake in Societal CDMO, Inc.
08/23/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/23/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Quarterly results
Docs: "Societal CDMO Reports Second Quarter 2023 Financial Results Recorded Q2 Revenue of $21.8 Million Signed Multiple New Business Agreements with New and Existing Customers Secured Schedule 1 Controlled Substance Manufacturing License from Drug Enforcement Agency; Allows Expansion into Manufacture of Psychedelic Drug Products Company to Host Webcast Today at 4:30 p.m. ET SAN DIEGO, CA, and GAINESVILLE, GA – August 14, 2023 — Societal CDMO, Inc. , a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported financial results for the second quarter and six months ended June 30, 2023. “The second quarter was a highly productive period. During the quarter, we co...",
"FILLED CAPSULES ORAL LIQUIDS TABLETS OPHTHALMIC DROPPERS STERILE INJECTABLES TOPICALS"
08/07/2023 SC 13G Cowen Prime Advisors LLC reports a 0% stake in RECRO PHARMA INC
08/02/2023 4 Lake Ryan David (CFO) has filed a Form 4 on Societal CDMO, Inc.
Txns: Paid exercise price by delivering 1,198 shares @ $0.85, valued at $1k
07/05/2023 4 Lake Ryan David (CFO) has filed a Form 4 on Societal CDMO, Inc.
Txns: Paid exercise price by delivering 1,198 shares @ $1.1, valued at $1.3k
06/06/2023 SC 13G/A First Light Asset Management, LLC reports a 16% stake in Societal CDMO, Inc.
06/02/2023 4 Lake Ryan David (CFO) has filed a Form 4 on Societal CDMO, Inc.
Txns: Paid exercise price by delivering 1,197 shares @ $0.7, valued at $837.9
05/26/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
05/19/2023 4 Miller James Charles (Director) has filed a Form 4 on Societal CDMO, Inc.
Txns: Granted 73,620 shares @ $0
Granted 27,229 options to buy @ $0.74, valued at $20.1k
05/19/2023 4 CHURCHILL WINSTON J (Director) has filed a Form 4 on Societal CDMO, Inc.
Txns: Granted 73,620 shares @ $0
Granted 27,229 options to buy @ $0.74, valued at $20.1k
05/19/2023 4 Cant Elena (Director) has filed a Form 4 on Societal CDMO, Inc.
Txns: Granted 73,620 shares @ $0
Granted 27,229 options to buy @ $0.74, valued at $20.1k
05/19/2023 4 Ashton William (Director) has filed a Form 4 on Societal CDMO, Inc.
Txns: Granted 73,620 shares @ $0
Granted 27,229 options to buy @ $0.74, valued at $20.1k
05/19/2023 4 Reasons Bryan M. (Director) has filed a Form 4 on Societal CDMO, Inc.
Txns: Granted 73,620 shares @ $0
Granted 27,229 options to buy @ $0.74, valued at $20.1k
05/19/2023 4 Weisman Wayne (Director) has filed a Form 4 on Societal CDMO, Inc.
Txns: Granted 73,620 shares @ $0
Granted 27,229 options to buy @ $0.74, valued at $20.1k
05/19/2023 4 Parks Laura L. (Director) has filed a Form 4 on Societal CDMO, Inc.
Txns: Granted 73,620 shares @ $0
Granted 27,229 options to buy @ $0.74, valued at $20.1k
05/18/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/10/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/10/2023 8-K Quarterly results
Docs: "Societal CDMO Reports First Quarter 2023 Financial Results Recorded Q1 Revenue of $21.5 Million Signed Multiple New Business Agreements with New and Existing Customers Granted FDA Approval for Manufacture of First Commercial Tablet Product Company to Host Webcast Today at 4:30 p.m. ET SAN DIEGO, CA, and GAINESVILLE, GA – May 10, 2023 — Societal CDMO, Inc. , a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported financial results for the first quarter ended March 31, 2023. “The company’s many achievements in 2022 placed Societal in an overall stronger financial position and paved the way for growth in 2023 and beyond. In the first quarter, we contin...",
"FILLED CAPSULES ORAL LIQUIDS TABLETS OPHTHALMIC DROPPERS STERILE INJECTABLES TOPICALS"
05/08/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
04/27/2023 4 AWM Investment Company, Inc. (10% Owner) has filed a Form 4 on Societal CDMO, Inc.
Txns: Sold 370,000 shares @ $0.7001, valued at $259k
04/06/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/04/2023 4 Lake Ryan David (CFO) has filed a Form 4 on Societal CDMO, Inc.
Txns: Paid exercise price by delivering 1,198 shares @ $1.19, valued at $1.4k
03/24/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/24/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/13/2023 8-K Regulation FD Disclosure  Interactive Data
03/02/2023 4 Lake Ryan David (CFO) has filed a Form 4 on Societal CDMO, Inc.
Txns: Paid exercise price by delivering 1,197 shares @ $1.47, valued at $1.8k
03/01/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/01/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy